Institute of Parasitology, Vetsuisse Faculty, University of Berne, Berne, Switzerland.
Antimicrob Agents Chemother. 2013 Aug;57(8):3829-35. doi: 10.1128/AAC.02569-12. Epub 2013 May 28.
Alveolar echinococcosis (AE) is a disease predominantly affecting the liver, with metacestodes (larvae) of the tapeworm Echinococcus multilocularis proliferating and exhibiting tumor-like infiltrative growth. For many years, chemotherapeutical treatment against alveolar echinococcosis has relied on the benzimidazoles albendazole and mebendazole, which require long treatment durations and exhibit parasitostatic rather than parasiticidal efficacy. Although benzimidazoles have been and still are beneficial for the patients, there is clearly a demand for alternative and more efficient treatment options. Aromatic dications, more precisely a small panel of di-N-aryl-diguanidino compounds, were screened for efficacy against E. multilocularis metacestodes in vitro. Only those with a thiophene core group were active against metacestodes, while furans were not. The most active compound, DB1127, was further investigated in terms of in vivo efficacy in mice experimentally infected with E. multilocularis metacestodes. This diguanidino compound was effective against AE when administered intraperitoneally but not when applied orally. Thus, thiophene-diguanidino derivatives with improved bioavailability when administered orally could lead to treatment options against AE.
泡型包虫病(AE)主要影响肝脏,绦虫多房棘球蚴的囊尾蚴(幼虫)增殖并表现出类似肿瘤的浸润性生长。多年来,针对泡型包虫病的化学治疗依赖于苯并咪唑类药物阿苯达唑和甲苯达唑,这些药物需要长时间治疗,并且表现出寄生虫静止而非寄生虫杀灭的效果。尽管苯并咪唑类药物已经并且仍然对患者有益,但显然需要替代和更有效的治疗选择。芳香二价阳离子,更准确地说是一小组二-N-芳基-二胍基化合物,在体外针对多房棘球蚴的囊尾蚴进行了疗效筛选。只有具有噻吩核心基团的化合物对囊尾蚴具有活性,而呋喃则没有。最活跃的化合物 DB1127 进一步在实验感染多房棘球蚴囊尾蚴的小鼠中进行了体内疗效研究。当腹腔内给药时,这种二胍基化合物对 AE 有效,但口服给药时无效。因此,当口服给药时具有改善生物利用度的噻吩二胍基衍生物可能会为 AE 的治疗提供选择。